Goldline Pharmaceutical Limited disclosed that its promoter and Whole Time Director, Swapan Khandelwal, has increased his stake in the company by acquiring 60,000 equity shares. The transaction, executed through the open market on June 22, 2026, represents 0.62% of the total issued and paid-up share capital. This acquisition signals increased promoter confidence in the pharmaceutical entity.

The disclosure was submitted to BSE Limited on June 23, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing detailed the change in shareholding pattern resulting from the open market purchase. Ruchi Sanket Modi, the Company Secretary cum Compliance Officer, authenticated the submission on behalf of the company.

Prior to the acquisition, Khandelwal held 2,749,988 equity shares, which accounted for 28.65% of the company's total voting capital. Following the purchase of 60,000 shares, his total holding has risen to 2,809,988 equity shares. This new stake translates to 29.27% of the total share capital, solidifying his position as a key shareholder in the firm.

The total equity share capital of Goldline Pharmaceutical Limited remains unchanged at 9,600,000 equity shares. There were no changes in the encumbrance status or holdings in warrants and convertible securities. The entire transaction was settled via the open market route without any preferential allotment or inter-se transfer mechanisms.

Shareholding Details

Goldline Pharmaceutical Limited reported a 45.2% rise in net profit to ₹411.71 lakh for the financial year ended March 31, 2026, compared to ₹283.43 lakh in the previous year. The company's revenue from operations increased 11.2% to ₹3,119.76 lakh from ₹2,805.57 lakh in FY25, driven by growth in its wholesale trade of pharmaceuticals business. Total income for the year stood at ₹3,119.88 lakh, up from ₹2,805.57 lakh in the prior year.

The Board of Directors approved the standalone audited financial results for the half-year and year ended March 31, 2026, at a meeting held on June 09, 2026. The results were reviewed by the Audit Committee and received an unmodified opinion from the statutory auditor, B Shroff & Co. The company was listed on the BSE SME Platform on May 19, 2026, subsequent to the reporting period.

Financial Performance

Profit before tax for FY26 increased to ₹538.54 lakh from ₹385.84 lakh in the previous year. Total expenses for the year rose to ₹2,581.34 lakh from ₹2,419.73 lakh, primarily due to higher employee benefit costs and purchases. Earnings per share (basic and diluted) improved to ₹5.97 from ₹4.11 in the prior year.

Balance Sheet and Cash Flows

The company's shareholder funds improved to ₹1,424.96 lakh as of March 31, 2026, compared to ₹1,026.03 lakh in the previous year, driven by an increase in reserves and surplus. Total assets stood at ₹2,887.09 lakh, up from ₹2,618.70 lakh. Cash and cash equivalents decreased to ₹59.24 lakh from ₹123.97 lakh at the end of the previous year.

Cash flow from operating activities for the year was ₹281.46 lakh, down from ₹318.12 lakh in FY25. The company utilized ₹340.41 lakh in financing activities, mainly towards repayment of borrowings and finance costs. Net cash and cash equivalents decreased by ₹64.73 lakh during the year.

Board Appointments

The Board appointed M/s. Kunal Dutt & Associates, Practicing Company Secretaries, as the Internal Auditor of the company for the financial year 2026-27 onwards. The firm is not related to any director or key managerial personnel of the company.